Highly Sensitive and Accurate Assessment of Minimal Residual Disease in Chronic Lymphocytic Leukemia Using the Novel CD160-ROR1 Assay
Undetectable minimal residual disease (MRD) in Chronic Lymphocytic Leukemia (CLL) has a favorable prognostic outcome compared with MRD that can be detected. This study investigated a flow cytometric assay (CD160-ROR1FCA) targeting the tumor-specific antigens CD160 and receptor tyrosine kinase-like o...
Main Authors: | , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2020-12-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2020.597730/full |
_version_ | 1819171594321264640 |
---|---|
author | Timothy W. Farren Timothy W. Farren Kaushik S. Sadanand Samir G. Agrawal Samir G. Agrawal |
author_facet | Timothy W. Farren Timothy W. Farren Kaushik S. Sadanand Samir G. Agrawal Samir G. Agrawal |
author_sort | Timothy W. Farren |
collection | DOAJ |
description | Undetectable minimal residual disease (MRD) in Chronic Lymphocytic Leukemia (CLL) has a favorable prognostic outcome compared with MRD that can be detected. This study investigated a flow cytometric assay (CD160-ROR1FCA) targeting the tumor-specific antigens CD160 and receptor tyrosine kinase-like orphan receptor 1 (ROR1), along with CD2, CD5, CD19, CD45. CD160-ROR1FCA was compared with the originally published 8-colour European Research Initiative for CLL (ERIC) gold-standard assay for CLL MRD detection. CD160-ROR1FCA had a limit of detection of 0.001% and showed strong correlation with ERIC (R = 0.98, p < 0.01) with negligible differences in MRD detection (bias -0.3152 95%CI 5.586 to -6.216). Using CD160-ROR1FCA, increased expression of both CD160 and ROR1 was found in Monoclonal B cell Lymphocytosis (MBL) compared to low-level polyclonal B-cell expansions (p < 0.01). Patients in CR and with undetectable MRD had a longer EFS (not reached) than those in CR but with detectable MRD (756 days, p < 0.01) versus 113 days in patients with partial remission (p < 0.01). Patients with MRD levels of >0.01 to 0.1% had a longer EFS (2,333 days), versus levels between 0.1 to 1% (1,049 days). CD160-ROR1FCA is a novel assay for routine CLL MRD measurement and for MBL detection. MRD status assessed by CD160-ROR1FCA after CLL treatment correlated with EFS. |
first_indexed | 2024-12-22T19:53:46Z |
format | Article |
id | doaj.art-dc1827ef33404c9caf9d62ecb95e7c02 |
institution | Directory Open Access Journal |
issn | 2234-943X |
language | English |
last_indexed | 2024-12-22T19:53:46Z |
publishDate | 2020-12-01 |
publisher | Frontiers Media S.A. |
record_format | Article |
series | Frontiers in Oncology |
spelling | doaj.art-dc1827ef33404c9caf9d62ecb95e7c022022-12-21T18:14:29ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2020-12-011010.3389/fonc.2020.597730597730Highly Sensitive and Accurate Assessment of Minimal Residual Disease in Chronic Lymphocytic Leukemia Using the Novel CD160-ROR1 AssayTimothy W. Farren0Timothy W. Farren1Kaushik S. Sadanand2Samir G. Agrawal3Samir G. Agrawal4Department of Haemato-Oncology and Immunophenotyping (SIHMDS), Barts Health NHS Trust, London, United KingdomImmunobiology, Blizard Institute, Queen Mary University of London, London, United KingdomImmunobiology, Blizard Institute, Queen Mary University of London, London, United KingdomDepartment of Haemato-Oncology and Immunophenotyping (SIHMDS), Barts Health NHS Trust, London, United KingdomImmunobiology, Blizard Institute, Queen Mary University of London, London, United KingdomUndetectable minimal residual disease (MRD) in Chronic Lymphocytic Leukemia (CLL) has a favorable prognostic outcome compared with MRD that can be detected. This study investigated a flow cytometric assay (CD160-ROR1FCA) targeting the tumor-specific antigens CD160 and receptor tyrosine kinase-like orphan receptor 1 (ROR1), along with CD2, CD5, CD19, CD45. CD160-ROR1FCA was compared with the originally published 8-colour European Research Initiative for CLL (ERIC) gold-standard assay for CLL MRD detection. CD160-ROR1FCA had a limit of detection of 0.001% and showed strong correlation with ERIC (R = 0.98, p < 0.01) with negligible differences in MRD detection (bias -0.3152 95%CI 5.586 to -6.216). Using CD160-ROR1FCA, increased expression of both CD160 and ROR1 was found in Monoclonal B cell Lymphocytosis (MBL) compared to low-level polyclonal B-cell expansions (p < 0.01). Patients in CR and with undetectable MRD had a longer EFS (not reached) than those in CR but with detectable MRD (756 days, p < 0.01) versus 113 days in patients with partial remission (p < 0.01). Patients with MRD levels of >0.01 to 0.1% had a longer EFS (2,333 days), versus levels between 0.1 to 1% (1,049 days). CD160-ROR1FCA is a novel assay for routine CLL MRD measurement and for MBL detection. MRD status assessed by CD160-ROR1FCA after CLL treatment correlated with EFS.https://www.frontiersin.org/articles/10.3389/fonc.2020.597730/fullCD160ROR-1minimal/measurable residual diseasechronic lymphocytic leukemiamonoclonal B-cell lymphocytosisflow cytometry |
spellingShingle | Timothy W. Farren Timothy W. Farren Kaushik S. Sadanand Samir G. Agrawal Samir G. Agrawal Highly Sensitive and Accurate Assessment of Minimal Residual Disease in Chronic Lymphocytic Leukemia Using the Novel CD160-ROR1 Assay Frontiers in Oncology CD160 ROR-1 minimal/measurable residual disease chronic lymphocytic leukemia monoclonal B-cell lymphocytosis flow cytometry |
title | Highly Sensitive and Accurate Assessment of Minimal Residual Disease in Chronic Lymphocytic Leukemia Using the Novel CD160-ROR1 Assay |
title_full | Highly Sensitive and Accurate Assessment of Minimal Residual Disease in Chronic Lymphocytic Leukemia Using the Novel CD160-ROR1 Assay |
title_fullStr | Highly Sensitive and Accurate Assessment of Minimal Residual Disease in Chronic Lymphocytic Leukemia Using the Novel CD160-ROR1 Assay |
title_full_unstemmed | Highly Sensitive and Accurate Assessment of Minimal Residual Disease in Chronic Lymphocytic Leukemia Using the Novel CD160-ROR1 Assay |
title_short | Highly Sensitive and Accurate Assessment of Minimal Residual Disease in Chronic Lymphocytic Leukemia Using the Novel CD160-ROR1 Assay |
title_sort | highly sensitive and accurate assessment of minimal residual disease in chronic lymphocytic leukemia using the novel cd160 ror1 assay |
topic | CD160 ROR-1 minimal/measurable residual disease chronic lymphocytic leukemia monoclonal B-cell lymphocytosis flow cytometry |
url | https://www.frontiersin.org/articles/10.3389/fonc.2020.597730/full |
work_keys_str_mv | AT timothywfarren highlysensitiveandaccurateassessmentofminimalresidualdiseaseinchroniclymphocyticleukemiausingthenovelcd160ror1assay AT timothywfarren highlysensitiveandaccurateassessmentofminimalresidualdiseaseinchroniclymphocyticleukemiausingthenovelcd160ror1assay AT kaushikssadanand highlysensitiveandaccurateassessmentofminimalresidualdiseaseinchroniclymphocyticleukemiausingthenovelcd160ror1assay AT samirgagrawal highlysensitiveandaccurateassessmentofminimalresidualdiseaseinchroniclymphocyticleukemiausingthenovelcd160ror1assay AT samirgagrawal highlysensitiveandaccurateassessmentofminimalresidualdiseaseinchroniclymphocyticleukemiausingthenovelcd160ror1assay |